A US-based KOL provides insight into the treatment pathway of HER2+ breast cancer with a focus on the beneficial impacts of Enhertu for metastatic patients and its displacement of other therapies. The KOL also highlights the promise of next-generation endocrine therapies and the potential of vaccine technologies. 

This interview was conducted on Aug. 1, 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.